Tissue urokinase-type plasminogen activator receptor levels in breast cancer.

S. J. Gong, SunYoung Rha, Hyuncheol Chung, N. C. Yoo, J. K. Roh, W. I. Yang, K. S. Lee, J. S. Min, B. S. Kim, H. C. Chung

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cancer invasion is induced by several proteolytic enzyme systems associated with the destruction of basement membrane and extracellular matrix. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have been reported as prognostic factors in breast cancer patients and plasminogen activation is regulated by various factors such as uPAR and growth factors. Thus, we examined the tissue levels of urokinase-type plasminogen activator receptor (uPAR) in breast cancer patients. Tissue uPAR levels were measured by ELISA assay in 268 breast cancer patients. The median and mean values of tissue uPAR level in breast cancer were 3.5 ng/mg cytosol protein and 4.8+/-3.6 ng/mg cytosol protein, respectively. Tissue uPAR level was the highest in T1 stage, but there was no statistical significance between the T stages (p>0.05), nor in nodal stage, in the value of uPAR according to progression. And the value of uPAR expression was not associated with estrogen and progesterone receptor status, number of involved node and percent of node involvement. In TNM stage, tissue uPAR levels were higher in patients with stage I-II than in patients with stage III-IV (p=0.027). In univariate analysis, nodal factor (p=0.002) and TNM stage (p=0.0004) were significant. But, multivariate analysis showed that TNM stage was the only significant prognostic factor (p=0.0002). These results suggest that uPAR is mainly associated with initial tumor invasion and other factors might be involved in later stages of cancer progression.

Original languageEnglish
Pages (from-to)301-305
Number of pages5
JournalInternational Journal of Molecular Medicine
Volume6
Issue number3
Publication statusPublished - 2000 Sep 1

Fingerprint

Urokinase Plasminogen Activator Receptors
Tissue Plasminogen Activator
Breast Neoplasms
Cytosol
Neoplasms
Plasminogen
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Progesterone Receptors
Basement Membrane
Estrogen Receptors
Extracellular Matrix
Intercellular Signaling Peptides and Proteins
Proteins
Peptide Hydrolases
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Genetics

Cite this

Gong, S. J. ; Rha, SunYoung ; Chung, Hyuncheol ; Yoo, N. C. ; Roh, J. K. ; Yang, W. I. ; Lee, K. S. ; Min, J. S. ; Kim, B. S. ; Chung, H. C. / Tissue urokinase-type plasminogen activator receptor levels in breast cancer. In: International Journal of Molecular Medicine. 2000 ; Vol. 6, No. 3. pp. 301-305.
@article{ad2700a4a4064a55b4386c4b73141613,
title = "Tissue urokinase-type plasminogen activator receptor levels in breast cancer.",
abstract = "Cancer invasion is induced by several proteolytic enzyme systems associated with the destruction of basement membrane and extracellular matrix. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have been reported as prognostic factors in breast cancer patients and plasminogen activation is regulated by various factors such as uPAR and growth factors. Thus, we examined the tissue levels of urokinase-type plasminogen activator receptor (uPAR) in breast cancer patients. Tissue uPAR levels were measured by ELISA assay in 268 breast cancer patients. The median and mean values of tissue uPAR level in breast cancer were 3.5 ng/mg cytosol protein and 4.8+/-3.6 ng/mg cytosol protein, respectively. Tissue uPAR level was the highest in T1 stage, but there was no statistical significance between the T stages (p>0.05), nor in nodal stage, in the value of uPAR according to progression. And the value of uPAR expression was not associated with estrogen and progesterone receptor status, number of involved node and percent of node involvement. In TNM stage, tissue uPAR levels were higher in patients with stage I-II than in patients with stage III-IV (p=0.027). In univariate analysis, nodal factor (p=0.002) and TNM stage (p=0.0004) were significant. But, multivariate analysis showed that TNM stage was the only significant prognostic factor (p=0.0002). These results suggest that uPAR is mainly associated with initial tumor invasion and other factors might be involved in later stages of cancer progression.",
author = "Gong, {S. J.} and SunYoung Rha and Hyuncheol Chung and Yoo, {N. C.} and Roh, {J. K.} and Yang, {W. I.} and Lee, {K. S.} and Min, {J. S.} and Kim, {B. S.} and Chung, {H. C.}",
year = "2000",
month = "9",
day = "1",
language = "English",
volume = "6",
pages = "301--305",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "3",

}

Gong, SJ, Rha, S, Chung, H, Yoo, NC, Roh, JK, Yang, WI, Lee, KS, Min, JS, Kim, BS & Chung, HC 2000, 'Tissue urokinase-type plasminogen activator receptor levels in breast cancer.', International Journal of Molecular Medicine, vol. 6, no. 3, pp. 301-305.

Tissue urokinase-type plasminogen activator receptor levels in breast cancer. / Gong, S. J.; Rha, SunYoung; Chung, Hyuncheol; Yoo, N. C.; Roh, J. K.; Yang, W. I.; Lee, K. S.; Min, J. S.; Kim, B. S.; Chung, H. C.

In: International Journal of Molecular Medicine, Vol. 6, No. 3, 01.09.2000, p. 301-305.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tissue urokinase-type plasminogen activator receptor levels in breast cancer.

AU - Gong, S. J.

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - Yoo, N. C.

AU - Roh, J. K.

AU - Yang, W. I.

AU - Lee, K. S.

AU - Min, J. S.

AU - Kim, B. S.

AU - Chung, H. C.

PY - 2000/9/1

Y1 - 2000/9/1

N2 - Cancer invasion is induced by several proteolytic enzyme systems associated with the destruction of basement membrane and extracellular matrix. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have been reported as prognostic factors in breast cancer patients and plasminogen activation is regulated by various factors such as uPAR and growth factors. Thus, we examined the tissue levels of urokinase-type plasminogen activator receptor (uPAR) in breast cancer patients. Tissue uPAR levels were measured by ELISA assay in 268 breast cancer patients. The median and mean values of tissue uPAR level in breast cancer were 3.5 ng/mg cytosol protein and 4.8+/-3.6 ng/mg cytosol protein, respectively. Tissue uPAR level was the highest in T1 stage, but there was no statistical significance between the T stages (p>0.05), nor in nodal stage, in the value of uPAR according to progression. And the value of uPAR expression was not associated with estrogen and progesterone receptor status, number of involved node and percent of node involvement. In TNM stage, tissue uPAR levels were higher in patients with stage I-II than in patients with stage III-IV (p=0.027). In univariate analysis, nodal factor (p=0.002) and TNM stage (p=0.0004) were significant. But, multivariate analysis showed that TNM stage was the only significant prognostic factor (p=0.0002). These results suggest that uPAR is mainly associated with initial tumor invasion and other factors might be involved in later stages of cancer progression.

AB - Cancer invasion is induced by several proteolytic enzyme systems associated with the destruction of basement membrane and extracellular matrix. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have been reported as prognostic factors in breast cancer patients and plasminogen activation is regulated by various factors such as uPAR and growth factors. Thus, we examined the tissue levels of urokinase-type plasminogen activator receptor (uPAR) in breast cancer patients. Tissue uPAR levels were measured by ELISA assay in 268 breast cancer patients. The median and mean values of tissue uPAR level in breast cancer were 3.5 ng/mg cytosol protein and 4.8+/-3.6 ng/mg cytosol protein, respectively. Tissue uPAR level was the highest in T1 stage, but there was no statistical significance between the T stages (p>0.05), nor in nodal stage, in the value of uPAR according to progression. And the value of uPAR expression was not associated with estrogen and progesterone receptor status, number of involved node and percent of node involvement. In TNM stage, tissue uPAR levels were higher in patients with stage I-II than in patients with stage III-IV (p=0.027). In univariate analysis, nodal factor (p=0.002) and TNM stage (p=0.0004) were significant. But, multivariate analysis showed that TNM stage was the only significant prognostic factor (p=0.0002). These results suggest that uPAR is mainly associated with initial tumor invasion and other factors might be involved in later stages of cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=0034266643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034266643&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 301

EP - 305

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 3

ER -